Because our group and others have identified increased circulating nonesterified fatty acids and ketones (7, 10) to be characteristic of the peripheral milieu in advanced nondiabetic human HF, an A H A -C la s s Disease progression in human heart failure is characterized by activation of neurohormonal pathways, including adrenergic and natriuretic peptide systems. This, in turn, leads to the sustained hydrolysis of triglycerides through the activation of hormone-sensitive and adipocyte triglyceride lipases, resulting in loss of adipocyte mass and suppression of leptin release from the fat cells. The release into the periphery of nonesterified fatty acids (NEFAs), known to be increased in heart failure, is handled by the liver, with increasing fatty acid oxidation (FAO).
When the rates of FAO exceed the capacity for downstream substrate oxidation via the Krebs cycle, this will result in a program of hepatic ketogenesis and, most likely, active acylcarnitine efflux into the periphery. This increase in circulating ketones, which has also been observed in the various stages of human heart failure, may be responsible for inducing metabolic reprogramming of the end-stage failing human heart with resulting increased utilization of beta-hydroxybutyrate (b-OHB) for fuel. The physiological consequences of increased circulating acylcarnitines, known to be associated with and possibly inflict insulin resistance, will require further investigation in the chronic syndrome of human heart failure. ANP ¼ atrial natriuretic peptide; BNP ¼ B-type natriuretic peptide. rame@uphs.upenn.edu.
